氯己定沐浴与常规沐浴预防普通内外科病房多重耐药菌及全因血流感染(ABATE Infection试验):整群随机试验
ABATE Infection试验为整群随机试验,纳入53家医院的194个非重症监护病房,比较常规沐浴与全员每日氯己定沐浴联合已知MRSA携带者莫匹罗星去定植。干预期与基线期相比,去定植组主要结局(单元归因MRSA或VRE临床培养)HR为0.79(0.73-0.87),常规护理组HR为0.87(0.79-0.95),两组相对HR无差异(p=0.17)。183 013例去定植组患者中报告25例(<1%)不良事件,均与氯己定相关,莫匹罗星无不良事件报告。结论认为在非重症患者中该去定植策略未显著减少多重耐药菌。
要点
- 在53家医院194个非重症病房中,全员氯己定沐浴加MRSA携带者莫匹罗星未显著减少单元归因MRSA或VRE临床培养。
- 去定植组干预期vs基线期HR 0.79(0.73-0.87),常规护理组HR 0.87(0.79-0.95),两组相对HR无差异(p=0.17)。
- 183 013例去定植组患者中报告25例(<1%)不良事件,均涉及氯己定,莫匹罗星无不良事件报告。
- 该策略在非重症病房的效应与重症监护病房中曾观察到的减少多重耐药菌和菌血症的效果不同。
适用人群与场景
- 53家HCA Healthcare affiliated医院中194个非重症监护病房(普通内外科单元)的患者。
- 干预期去定植组183 013例,常规护理组156 889例;基线期189 081例。
处置流程与药物剂量
- 去定植组:所有患者每日氯己定沐浴,已知MRSA携带者加用莫匹罗星。
- 常规护理组:常规沐浴。
研究设计与关键结果
- 整群随机试验,53家医院194个非重症病房,基线期12个月(2013年3月1日至2014年2月28日),导入期2个月(2014年4月1日至5月31日),干预期21个月(2014年6月1日至2016年2月29日)。
- 主要结局单元归因MRSA或VRE临床培养:去定植组干预期vs基线期HR 0.79(0.73-0.87),常规护理组HR 0.87(0.79-0.95),两组相对HR无差异(p=0.17)。
- 183 013例去定植组患者中报告25例(<1%)不良事件,均涉及氯己定;莫匹罗星无不良事件报告。
证据类型、等级与局限
- 证据类型:整群随机试验(ABATE Infection trial),注册号NCT02063867。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在非重症患者中,全员氯己定沐浴联合MRSA携带者靶向莫匹罗星未显著减少多重耐药菌。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Universal skin and nasal decolonisation reduces multidrug-resistant pathogens and bloodstream infections in intensive care units. The effect of universal decolonisation on pathogens and infections in non-critical-care units is unknown. The aim of the ABATE Infection trial was to evaluate the use of chlorhexidine bathing in non-critical-care units, with an intervention similar to one that was found to reduce multidrug-resistant organisms and bacteraemia in intensive care units.
METHODS: The ABATE Infection (active bathing to eliminate infection) trial was a cluster-randomised trial of 53 hospitals comparing routine bathing to decolonisation with universal chlorhexidine and targeted nasal mupirocin in non-critical-care units. The trial was done in hospitals affiliated with HCA Healthcare and consisted of a 12-month baseline period from March 1, 2013, to Feb 28, 2014, a 2-month phase-in period from April 1, 2014, to May 31, 2014, and a 21-month intervention period from June 1, 2014, to Feb 29, 2016. Hospitals were randomised and their participating non-critical-care units assigned to either routine care or daily chlorhexidine bathing for all patients plus mupirocin for known methicillin-resistant Staphylococcus aureus (MRSA) carriers. The primary outcome was MRSA or vancomycin-resistant enterococcus clinical cultures attributed to participating units, measured in the unadjusted, intention-to-treat population as the HR for the intervention period versus the baseline period in the decolonisation group versus the HR in the routine care group. Proportional hazards models assessed differences in outcome reductions across groups, accounting for clustering within hospitals. This trial is registered with ClinicalTrials.gov, number NCT02063867.
FINDINGS: There were 189 081 patients in the baseline period and 339 902 patients (156 889 patients in the routine care group and 183 013 patients in the decolonisation group) in the intervention period across 194 non-critical-care units in 53 hospitals. For the primary outcome of unit-attributable MRSA-positive or VRE-positive clinical cultures (figure 2), the HR for the intervention period versus the baseline period was 0·79 (0·73-0·87) in the decolonisation group versus 0·87 (95% CI 0·79-0·95) in the routine care group. No difference was seen in the relative HRs (p=0·17). There were 25 (<1%) adverse events, all involving chlorhexidine, among 183 013 patients in units assigned to chlorhexidine, and none were reported for mupirocin.
INTERPRETATION: Decolonisation with universal chlorhexidine bathing and targeted mupirocin for MRSA carriers did not significantly reduce multidrug-resistant organisms in non-critical-care patients.
FUNDING: National Institutes of Health.
参考来源
- Huang SS, Septimus E, Kleinman K, et al. Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial. Lancet. 2019. PMID: 30850112. doi:10.1016/S0140-6736(18)32593-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。